NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Vaccines for Emerging and Endemic Diseases > Oxford Ebola vaccine study moves to next phase

Oxford Ebola vaccine study moves to next phase

15 July 2015 · Listed under Vaccines for Emerging and Endemic Diseases

Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen, with part of the study supported by the NIHR Oxford Biomedical Research Centre.

The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research (INSERM) as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert (IT) and the Janssen Pharmaceutical Companies of Johnson & Johnson.

The EBOVAC2 project is funded under a grant from the European Commission’s Innovative Medicine Initiative Ebola+ programme which was launched in response to the Ebola virus disease outbreak. The EBOVAC2 project aims to assess the safety and immunogenicity of a novel prime boost preventative vaccine regimen against Ebola Virus Disease (EVD).

The original development of the prime boost vaccine regimen was accelerated in response to the outbreak of Ebola virus disease in West Africa, which has now claimed more than 11,000 lives. Although the number of confirmed EVD cases has decreased in recent months, new cases of EVD in Liberia, which had been declared Ebola free, highlight that a preventative vaccine may still be needed to control the spread of disease.

The Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics, has started enrolling volunteers for the phase II study this month, with additional French sites coordinated by Inserm anticipated to start recruitment in August.  An additional study is planned to follow in several African countries.

The Phase II study aims to recruit more than 600 healthy adult volunteers in the UK and France.

In the UK, volunteers for the study, aged 18–65 years, are likely to come largely from the Oxfordshire region, and will be asked to make a maximum of 17 visits to the Oxford Vaccine Group site on the city’s Churchill Hospital site over a period of a year. The Oxford study is supported by the NIHR Oxford Biomedical Research Centre, a partnership between the University of Oxford and Oxford University Hospitals Trust, funded by the National Institute for Health Research.

The vaccine regimen used in the study involves two different components, given a few weeks apart. The first dose is intended to stimulate, or ‘prime’, an initial immune response. The second dose then is designed to ‘boost’ the level of the body’s immune response further.

Neither vaccine component contains any replicating virus, so it is not possible to be infected with Ebola.

In pre-clinical studies of this vaccine regimen conducted in collaboration with the National Institutes of Health complete protection from death due to Ebola was achieved against the Kikwit variant – which is highly similar to the virus causing the current outbreak in Western Africa. Preliminary results from the first phase of the clinical study, conducted in Oxford and involving 87 volunteers, indicated that the prime-boost vaccine regimen is immunogenic, regardless of the order of vaccine administration, and only provoked temporary reactions normally expected from vaccination.

People interested in volunteering for the clinical study can find out more information at www.ebolavaccine.org.uk.

In addition to the Phase II study being conducted in the UK and France, similar studies are also starting in Africa to establish how robust the immune response is to the Ebola vaccine regimen. Given the compressed nature of this development program, the Phase II studies are anticipated to be conducted in parallel with the planned safety and immunogenicity study in Sierra Leone as part of EBOVAC1.

Prof Andrew Pollard, Director of the Oxford Vaccine Group, said: ‘The devastating Ebola epidemic in Guinea, Liberia and Sierra Leone has shown how urgently we need a safe and effective vaccine. That goal has brought together manufacturers, public health bodies and research regulators to accelerate these studies of new Ebola vaccines. The results of the first phase, which are due to be published shortly, are encouraging. We are appealing, once again, for volunteers to come forward and help us in the second stage of this vital work.’

The objectives of the EBOVAC2 study are to determine further the vaccine regimen’s safety profile and how well it stimulates the immune system to protect against Ebola infection. The team also want to work out the best timing for each of the vaccines. Volunteers will therefore be put on different schedules, where the gap between ‘prime’ and ‘boost’ dose will be 28, 56 or 84 days.

The immune responses that the vaccine generates – both antibodies and T cells – will also be measured over a period of one year.

Another team in the Jenner Institute has been studying a different Ebola vaccine (ChAd3 EBOZ) funded by the Wellcome Trust and the Department for International Development and developed with GSK/ US National Institutes of Health. Led by Professor Adrian Hill, preliminary results from the phase I studies conducted earlier this year have shown that this vaccine has a good safety profile and stimulates an immune response against the Ebola virus. Professor Hill’s team has since started on a phase I trial of a boost to this vaccine and recruitment is ongoing.

← BRC supports Oxford Ebola summit
First trial for childhood illness vaccine →

News

  • Environmental impact of 57,000 multi-ingredient processed foods revealed for first time 9 August 2022
  • £1.2m award to improve diagnosis of emergency spinal condition 4 August 2022
  • Workshop helps public contributors become ‘citizen experts’ on equality and diversity in research 4 August 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre